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Introduction: Fibrosingmediastinitis (FM) is a rare but fatal disease characterized by an excessive ﬁbrotic reaction
in the mediastinum, which can lead to life-threatening stenosis of the pulmonary veins (PV). Catheter-based
intervention is currently the only viable option for therapy. However, the current literature on how best to man-
age these difﬁcult cases, especially in regards to sequential interventions and their potential complications is very
limited.
Methods: We searched through a database of all patients who have undergone PV interventions at the Earl H.
Wood Cardiac Catheterization Laboratory in Mayo Clinic, Rochester. From this collection, we selected patients
that underwent PV intervention to relieve stenosis secondary to FM.
Results: Eight patientswere identiﬁed, with amean age of 41 years (24–59 years). Fiveweremen, and threewere
women. Three patients underwent balloon angioplasty alone, and ﬁve patients had stents placed. Themajority of
patients had acute hemodynamic and symptomatic improvement. More than one intervention was required in
ﬁve patients, four patients had at least one episode of restenosis, and four patients died within four weeks of
their ﬁrst PV intervention.
Conclusions:Wedescribe the largest reported case series of catheter-based intervention for PV stenosis in FM. Al-
though catheter-based therapy improved hemodynamics, short-term vascular patency, and patient symptoms,
the rate of life-threatening complications, restenosis, and mortality associated with these interventions was
found to be high. Despite these associated risks, catheter-based intervention is the only palliative option available
to improvequality of life in severely symptomatic patientswith PV stenosis and FM. Patientswith PV stenosis and
FM (especially thosewith bilateral disease) have an overall poor prognosis in spite of undergoing these interven-
tions due to the progressive and recalcitrant nature of the disease. This underscores the need for further innova-
tive approaches to manage this disease.
© 2015 Mayo Clinic. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fibrosing mediastinitis (FM), also known as collagenosis or scleros-
ing mediastinitis [1,2] is a rare but fatal disease with relatively few
therapeutic options. It is thought to occur due to exposure to the
Histoplasma capsulatum antigen within the mediastinum, triggering an
intense inﬂammatory host response resulting in proliferation and inva-
sion of ﬁbrous tissue into vital structures [3,4]. One complication of the
ﬁbrotic reaction is pulmonary vein (PV) stenosis, previously describedDiseases, 200 First Street SW,
irvatham).
and Ltd. This is an open access articlein case reports and series [1,3–12]. Diagnosis of PV stenosis is challeng-
ing due to its gradual onset of nonspeciﬁc symptoms including fatigue
and dyspnea, and thus presentation is typically delayed. In the late
stages of this disease, recurrent episodes of pulmonary edema and he-
moptysis can occur, eventually becoming fatal [6,7,13].
Medical and surgical therapies for FM remain largely ineffective due
to its extensive ﬁbrotic invasion of mediastinal structures [2,14–18]. For
those patients suffering from PV stenosis, angioplasty and stent deploy-
ment are potential treatment options. Relieving obstructionwith timely
angioplasty in PV stenosis caused by other etiologies (i.e. pulmonary
vein isolation for atrial ﬁbrillation) normalizes venous ﬂow into the
left atrium [19,20]; however, there is limited data on how best to man-
age PV stenosis caused by FM [1,5–7,21].under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patients with PV stenosis due to FM.
2. Methods
We searched amongst all patients who had undergone pulmonary
vein intervention at the Earl H. Wood Cardiac Catheterization
Laboratory in Mayo Clinic Rochester. From this cohort, we identiﬁed
eight patients who had at least one pulmonary vein procedure (angio-
plasty +/− stent placement) for PV stenosis due to FM. We then
performed a detailed chart review to evaluate patient presentation,
symptoms, interventions, complications, and outcomes.
3. Results
We identiﬁed eight cases of PV stenosis due to FM that underwent
catheter-based intervention. There were ﬁve men and three women,
with a mean age at presentation of 41 years (range 24–59 years).
In our series of eight patients, a total of eighteen catheterizations
were performed, including one aborted procedure and seventeen angio-
plasties either with balloon, stent, or both (three patients had balloon
angioplasty only). Seven patients had severe stenosis in two or more
PVs (Table 1). Five of our patients required more than one intervention.
Acute hemodynamic improvement was seen in all eight patients with
balloon angioplasty +/− stent placement (Table 2).
3.1. Case 1
A 27-year-old woman with six months of progressively worsening
dyspnea developed respiratory failure during diagnostic bronchoscopy.
CT angiogram (CTA) of the chest showed bilateral patchy ground glass
opacities suggestive of pulmonary edema with occlusion of both the
right lower pulmonary vein (RLPV) and left upper pulmonary vein
(LUPV) and a marked focal narrowing of the right upper pulmonary
vein (RUPV). Successful balloon angioplasty of RUPV was done but the
patient continued to clinically deteriorate and died in two days. Autopsy
revealed an 8 cm ﬁbrosing mediastinal mass with fungal stains consis-
tent with Histoplasma, as well as partial encasement of the right and
left pulmonary hilar regions with constriction or obliteration of the
vasculature.
3.2. Case 2
A 52-year-oldmanwith a history of FM and a prior pericardial patch
enlargement of the RLPV 12 years ago presented with gradual worsen-
ing of fatigue and dyspnea on exertion. CTA demonstrated stenosis of
the RLPV and occlusion of all other pulmonary veins. No intervention
was performed initially due to lack of signiﬁcant gradient across this
lesion. The patient's symptoms worsened over the next ﬁve months
and required two balloon angioplasties in the RLPV. The patient wasTable 1
Patient characteristics.
Case Age⁎ Sex Pulmonary veins involved
RUPV RMPV RLPV LUPV LLPV
1 27 F Stenosed Absent Occluded Occluded Patent
2 52 M Occluded Absent Stenosed Occluded Occluded
3 47 F Occluded Absent Stenosed Occluded Stenosed
4 38 M Occluded Absent Occluded Stenosed Stenosed
5 59 M Stenosed Absent Stenosed Occluded Patent
6 42 M Stenosed Occluded Patent Absent Absent
7 24 F Stenosed Absent Occluded Patent Patent
8 43 M Occluded Absent Stenosed Stenosed Stenosed
⁎ Age at ﬁrst catheterization; left upper pulmonary vein; LLPV, left lower pulmo-
nary vein; PV, pulmonary vein; RLPV, right lower pulmonary vein; RUPV, right upper
pulmonary vein.asymptomatic afterwards but passed away the following month from
complications of a newly diagnosed metastatic cancer.
3.3. Case 3
A 47-year-old man with FM was admitted for worsening shortness
of breath over the past three months with pulmonary edema. CTA
showed severe stenosis of the left lower pulmonary vein (LLPV) and
the right middle pulmonary vein (RMPV) along with occlusion of
LUPV and RUPV. The patient underwent balloon angioplasty followed
by placement of two stents in the LLPV and RMPV respectively. This
resulted in a signiﬁcant improvement in hemodynamics. Repeat CTA
was performed at 1month, 1 year, 1.5 years, and 4 years post procedure
and showed no signiﬁcant restenosis; the patient has remained
asymptomatic.
3.4. Case 4
A 38-year-old woman with FM presented with six months of wors-
ening shortness of breath and hypoxia requiring 4 L of oxygen at rest.
CTA (Fig. 1) demonstrated that the right pulmonary veins were occlud-
ed, and the left pulmonary veins were stenotic but patent. Balloon
angioplasty was performed in the LUPV resulting in improved symp-
toms. Ninemonths later, symptoms recurred requiring a repeat balloon
angioplasty of the LLPV. At three-month follow-up, the patient was still
requiring 4 L of oxygen at rest and remained dyspneicwith exertion, but
symptoms had improved while at rest.
3.5. Case 5
A 59-year-old male with FM presented with gradually worsening
hemoptysis and exercise intolerance for the last two years. Angiography
revealed stenosis of the RLPV and RUPV and occlusion of the LUPV
(Fig. 2). A stent was successfully placed in the RLPV but the patient de-
veloped severe chest pain during the procedure. An occlusive thrombus
was found in the left anterior descending artery, which was removed,
and the patient was started on eptiﬁbatide and bivalirudin infusions.
A drug eluting stent was then placed in the RUPV, but the patient
developed severe intra-procedural hemoptysis. At this time, all
anticoagulation was stopped and an endobronchial blocker was placed
in the left main stem bronchus. Overnight, the patient suffered a large
embolic stroke with temporal lobe herniation and died.
3.6. Case 6
A 42-year-old male with FM and history of a left pneumonectomy
presented with worsening hemoptysis and exercise intolerance over
the last six months. CTA demonstrated high-grade stenosis of RUPV
and chronic RMPV occlusion. Two stents were initially placed in the
RUPV and in the next ten months, two more balloon angioplasties
were performed for restenosis; despite this, the RUPV re-occluded
(Fig. 3). Rotational atherectomy was then performed within the stent
followed by cutting balloon angioplasty, but it resulted an acute in-
stent thrombosis the next day. In the next eight months, the patient re-
quired threemore angioplastieswith cutting balloons aswell as another
stent in the RUPV. The patient is now being considered for a heart and
lung transplant.
3.7. Case 7
A 24-year-old womanwith FM and vonWillebrand disease present-
ed with worsening dyspnea on exertion over the course of the last
month. CTA revealed complete occlusion of the RLPV and near complete
occlusion of the RUPV. A stentwas successfully placed in the RUPV but it
re-stenosed in six months with resultant intermittent hemoptysis re-
quiring another stent. The second stent lasted for thirteen months
Table 2
Pulmonary vein interventions and outcomes.
Case Intervention # Vessel Interventions § Clinical response b Complications
Balloon Stent
1 1 RUPV 8 × 20 N/A None Death
2 1 RLPV 12 × 30 N/A None Restenosis
2 RLPV 15 × 40 N/A 1 Death
3 1 LLPV 8 × 20 10 × 19€ 48 None
RMPV N/A 8 × 27μ
4 1 LUPV 12 × 30 N/A 9 None
2 LLPV 18 × 30 N/A 3 None
5 1 RLPV 3 × 20 10 × 19€ None STEMI, Stroke, Death
RUPV 4.5 × 15 4 × 28£
6 1 RUPV 5.5 × 15 8 × 17∞
8 × 17∞
4 Restenosis
2 RUPV 8 × 20 N/A 4 Restenosis
3 RUPV 10 × 30 N/A 2 Restenosis
4 RUPV RA¥ None Stent thrombosis
6 × 40* N/A
5 RUPV 4 × 15 7 × 15∏
4 × 12Ῥ
2 Restenosis
6 RUPV 8 × 20 N/A 3 Restenosis
7 RUPV 8 × 20 N/A 3 Restenosis
8 RUPV 6 × 40* 4 × 16ȹ None None
7 1 RUPV 8 × 20 10 × 29€ 6 Restenosis
2 RUPV 10 × 30 10 × 29€ 4 Restenosis
8 1 LLPV N/A 10 × 19€ 8 Restenosis
LUPV N/A 10 × 19€
2 LLPV 10 × 20 N/A 7 Restenosis
LUPV 10 × 20 N/A
RLPV 12 × 30 10 × 19€
3 LLPV 8 × 20* N/A None Hemoptysis, Death
* Cutting balloon angioplasty; § size inmillimeters; b duration inmonths; μ Visipro stent; € Cordis Genesis stent; £ Xience drug eluting stent; ∞ Express LD iliac biliary stent;∏ Herculink
renal and biliary stent; Ῥ Promus element stent;ȹ Promus premier stent; ¥ RA, rotational atherectomy, 2.15 rotablator catheter; LUPV, left upper pulmonary vein; LLPV, left lower pul-
monary vein; PV, pulmonary vein; RLPV, right lower pulmonary vein; RUPV, right upper pulmonary vein; RMPV, right middle pulmonary vein.
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stents were placed, but subsequently, several embolizations were per-
formed in the pulmonary arteries with some improvement in the he-
moptysis. Four years following these embolizations, the patient
continues to have occasional hemoptysis and suffers from severe dys-
pnea on exertion.
3.8. Case 8
A 43-year-old male with FM presented for worsening dyspnea over
the last three months. Angiography revealed signiﬁcant stenoses of the
LUPV and LLPV and complete occlusion of the RUPV, with only slight
narrowing of the RLPV. Two stents placed in the LUPV and LLPV re-
stenosed in eight months requiring balloon angioplasty and the RLPV
stenosis worsened. A stent was then placed in RLPV and the patient
was started on oral Sirolimus. All three veins re-stenosed in seven
months and a cutting balloon angioplasty in the LLPV resulted in severe
hemoptysis. Bronchoscopy revealed clots obstructing the leftmain stemFig. 1. Extensive involvement of ﬁbrosingmediastinitis. (A) Transverse section of mediastinal ﬁ
left superior and inferior pulmonary veins. (C) Coronal section of mediastinal ﬁbrotic mass resbronchus and bleeding continued despite use of protamine and an
endobronchial blocker. The patient died of inadequate ventilation four
days later. The autopsy revealed old thrombotic occlusion of the RUPV,
and narrowing of the other three PVs without a clear source of pulmo-
nary hemorrhage.
4. Discussion
4.1. Response to intervention of the pulmonary veins in
ﬁbrosing mediastinitis
PV stenosis due to FM is a morbid condition leading to severe dys-
pnea and hemoptysis and can be life-threatening [6,7,13]. Our case se-
ries describes the use of balloon angioplasty with or without stent
placement to treat stenotic PVs (Table 2). In all patients, immediate he-
modynamic and/or angiographic improvement was achieved with per-
cutaneous intervention. While a majority of our patients were afforded
temporary relief by their procedures, the prognosis for these patientsbroticmass resulting in extrinsic compression of RUL artery. (B) Coronal section of stenotic
ulting in extrinsic compression of RUL artery.
Fig. 2. 3D Reconstruction of pulmonary veins showing stenosis of RUPV and RLPV as well
as occlusion of LUPV.
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the one unrelated death due to metastatic cancer). This number is
similar to that previously reported in patients with FMwith seriousme-
diastinal structural compromise without any intervention [16]. Of note,
all four patients that died in our series had bilateral disease. Not surpris-
ingly, bilateral mediastinal involvement by FM has been previously as-
sociated with a worse prognosis [14]. Thus, interventions for this
patient group may afford limited symptomatic relief without affecting
mortality.4.2. Restenosis of pulmonary veins in ﬁbrosing mediastinitis
Restenosis was the most common complication in our cohort.
Among our cohort of eight patients, four developed restenosis. The
50% rate of restenosis observed in our cohort would still be an underes-
timation at the best, as two of the remaining four patients (case #1 and
case #5) died shortly after the procedure. All four of these patients re-
quired repeat interventions and the total number of interventions
ranged from 2 to 8. This is consistent with previous reports. AlbersFig. 3. Right upper pulmonary vein stenosis requiring multiple interventions. (A) Angiogret al. reported that restenosis occurred in about 37% of their patients un-
dergoing PV interventionwith only 25% of thembeing symptomatic and
requiring re-intervention [21]. Furthermore, the time to restenosis var-
ied signiﬁcantly from patient to patient. One extreme example is illus-
trated by case #6, in which eight separate interventions to the RUPV
were required because of continued restenosis recurring over a period
of 19 months, including cutting and standard balloon angioplasty,
stent placement, and rotational atherectomy.
In-stent restenosis occurred in three of our eight patients and was
treated with various techniques in each patient. In case #6, restenosis
occurred after three separate interventions. Rotational atherectomy
was used to treat complete occlusion of a PV stent but resulted in
acute stent thrombosis requiring the use of an aspiration catheter. Addi-
tionally, cutting balloon angioplasty was also attempted in cases #6 and
#8, but was met with limited success resulting in restenosis within two
to four months. In case #7, in-stent restenosis occurred quickly within
months of initial stent placement in the RUPV. In case #8, adjuvant ther-
apy with oral sirolimus was tried, but restenosis still occurred in 7
months. Although rotational atherectomy and sirolimus were tried in
two of our cases to treat restenosis, they were unsuccessful resulting
in acute stent thrombosis and recurring stenosis respectively.We advise
caution when trying these approaches in patients with FM and PV ste-
nosis and suggest limiting their use to select patients with recalcitrant
lesions.4.3. Cardiac and pulmonary complications of intervention
In addition to the risk of restenosis associated with PV intervention,
hemoptysis, severe pulmonary hemorrhage, dissection [22], pulmonary
vein rupture [23,24], and embolic events [25] are additional procedural
risks. Within our cohort, one patient had an intra-procedural ST eleva-
tion myocardial infarction and necessitated the use of thrombectomy.
The same patient later suffered a massive stroke resulting in death
(case #5). The strokewas cardio-embolic in nature thought to be a com-
plication of his prior PV intervention. Albers et al. also reported a case of
PV stent placement complicated by stroke and resulting in deathwithin
19 days of the procedure [21]. We believe this occurred either due to
formation of a ﬁstula between the bronchial side and the left atrial
side at the time of the intervention causing air embolism and hemopty-
sis or due to systemic embolization of casts formed within the pulmo-
nary vein during the procedure. Thus, there exists a potential for
stroke/air embolism during these procedures due to the inﬁltrative
nature of the disease or the hypercoagulable state of patient.
Hemoptysis complicated three interventions in cases #5, #7 and #8.
In case #5, hemoptysis developed during the procedure afterwe started
eptiﬁbatide and bivalirudin. An endobronchial blockerwas placed in theaphic images showing in-stent restenosis (B) Angiographic images post-angioplasty.
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achieve hemostasis. Case #7 had von Willebrand disease and the
hemoptysis was associatedwith the use of aspirin, clopidogrel andwar-
farin. Hemoptysis improved after stopping all anti-coagulants and anti-
thrombotic agents and required embolization, which also averted a cat-
astrophic event. However, multiple embolizations to the pulmonary ar-
teries were done before a sustainable improvement in hemoptysis was
achieved. In case #8, severe hemoptysis with large clots obstructing the
left main bronchus occurred after cutting balloon angioplasty was per-
formed in the LLPV. This necessitated the use of an endobronchial
blocker to attempt to mitigate intra-bronchial bleeding, though this
continued despite multiple procedures, culminating in patient death.
Two of the cases presented in this series have been previously re-
ported to illustrate FM and its associated structural compromise in the
mediastinum. Case #4 was described in an individual case report on
PV stenosis due to FM [26]. Case #8 was part of a series described by
Ferguson et al. with regard to outcomes of intravascular thoracic vessel
stent placement in FM, though only one patient in this series had PV
stent placement [12]. We build upon these previous reports in our cur-
rent series of patients, in order to further highlight the current options
and complications associated with PV stenosis in FM. The high rate of
life-threatening complications and mortality associated with these in-
terventions further underscores the limitations of these procedures to
afford temporary symptomatic relief despite being the only palliative
option in severely symptomatic patients.
Due to the rare nature of FM, extrapolation is needed from successes
achievedwith other etiologies of PV stenosis (e.g. pulmonary vein isola-
tion for atrial ﬁbrillation) in order to develop innovative procedures to
improve outcomes in this extremely sick population. Cutting balloon
angioplasty is shown to complement standard balloon angioplasty and
improve the patency for pulmonary vein in-stent stenosis [27]. In addi-
tion, improved outcomes are seen when larger diameter stents were
used (N10 mm) [28]. The use of oral sirolimus, reported by Bromberg-
Marin et al., prevented restenosis up to 12–18months [29]. These tech-
niques could be adopted when treating patients with PV stenosis and
FM. However, it is clear that larger and systematic studies are necessary
to describe and validate possible beneﬁt of these interventions.
5. Conclusion
Pulmonary vein stenosis due to ﬁbrosing mediastinitis remains a
condition with signiﬁcant morbidity with few treatment options. This
series demonstrates that while short-term hemodynamic and proce-
dural beneﬁt can be achieved with catheter-based interventions, the
risk of complications and overall prognosis still remains poor. Early in-
tervention is critical in these patients as it is very difﬁcult to allow for
longstanding beneﬁt at later stages of the disease but this comes at an
expense of high rate of restenosis, procedural complications andmortal-
ity. Further innovative therapies are needed to provide better treatment
options for this high-risk patient population.
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